Cancer/testis antigen 1; NY-ESO-1
CAT No: ta-512
Synonyms/Alias:Cancer/testis antigen 1 (139-156); NY-ESO-1 (139-156)
Cancer/testis antigen 1 (139-156) is a synthetic peptide fragment derived from the larger cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1, which is a well-characterized tumor-associated antigen. This peptide encompasses amino acids 139 to 156 of the full-length protein and is recognized for its immunogenic properties, particularly in the context of tumor immunology. As a member of the cancer/testis antigen family, it is expressed in a wide range of malignancies but is typically absent in normal adult tissues except for the testis. The unique expression profile and well-defined epitope sequence make this peptide a valuable tool in the study of antigen processing, immune recognition, and cancer-specific immune responses.
Epitope mapping: Cancer/testis antigen 1 (139-156) is widely utilized in epitope mapping studies to identify and characterize T-cell and B-cell epitopes relevant to tumor immunology. By using this defined peptide sequence, researchers can investigate the specific regions of CTAG1 that are recognized by cytotoxic T lymphocytes or antibodies in patient-derived samples. These studies are essential for understanding antigenic determinants that contribute to immune surveillance and tumor-specific immune responses, thereby informing the design of next-generation immunotherapeutic strategies.
Immunological assay development: The peptide serves as a standard reagent in the development and validation of immunological assays, such as ELISPOT, intracellular cytokine staining, and peptide-MHC tetramer assays. Its well-characterized sequence allows for the reliable detection and quantification of antigen-specific T-cell responses in preclinical and translational research settings. Utilizing this peptide in assay development enables the assessment of immune activation, functional avidity, and the breadth of T-cell recognition against cancer/testis antigens, supporting immunomonitoring in oncology research.
Vaccine research: Cancer/testis antigen 1 (139-156) is a critical component in experimental cancer vaccine studies, where it is employed to evaluate the immunogenicity of peptide-based vaccine candidates. Its inclusion in vaccine formulations or as a challenge antigen allows researchers to monitor antigen-specific immune responses, assess the induction of cellular immunity, and optimize peptide selection for maximal immunogenic potential. These studies contribute to the rational design of peptide vaccines targeting tumor-associated antigens.
T-cell receptor specificity studies: The defined sequence of this peptide is instrumental in dissecting the specificity and cross-reactivity of T-cell receptors (TCRs) derived from tumor-infiltrating lymphocytes or engineered T-cell lines. By presenting the peptide in the context of major histocompatibility complex (MHC) molecules, investigators can analyze TCR binding, signaling, and functional outcomes, providing insights into the molecular interactions that govern antigen recognition and the potential for off-target effects in adoptive cell therapy development.
Antigen processing and presentation research: The peptide is frequently used in studies aimed at elucidating the mechanisms of antigen processing and presentation in tumor cells and antigen-presenting cells. By employing this defined fragment, researchers can model peptide loading onto MHC class I molecules, evaluate proteasomal processing, and investigate the efficiency of antigen presentation pathways. Such research is fundamental for understanding how tumor antigens are displayed to the immune system and for identifying strategies to enhance antigen presentation in cancer immunotherapy contexts.
3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
4. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More